Results
105
Companys with strong funding and high growth potential
105 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 171.10 | -2.4% | -42.0% | SEK 15.1b | SEK 290.60 | PS50.5x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.22 | 6.1% | -26.5% | US$139.7m | US$8.65 | PS64.4x | E70.4% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €536.34 | 0.1% | 6.1% | €28.8b | €568.10 | PS19.4x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$5.99 | -3.7% | 63.7% | US$1.4b | US$11.28 | PS6.7x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
ARGN.F | €525.60 | 0% | n/a | €28.8b | €556.72 | PS19.4x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
BIOABS | SEK 173.90 | 0% | n/a | SEK 15.1b | SEK 295.36 | PS50.5x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
AKES.F | HK$8.48 | 36.8% | n/a | HK$55.4b | HK$8.69 | PS26.8x | E54.7% | n/a | Pharmaceuticals & Biotech | ||
ARGXB | €481.80 | -0.9% | 1.4% | €28.8b | €510.33 | PS19.4x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 16.89 | -0.06% | -37.0% | SEK 15.1b | SEK 28.69 | PS50.5x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
0QW0 | €475.69 | -2.0% | -0.3% | €28.8b | €503.85 | PS19.4x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
BPMC | US$90.94 | 8.1% | 84.2% | US$5.7b | US$127.35 | PS15.9x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
0HOJ | US$92.15 | 4.0% | 84.0% | US$5.8b | US$129.05 | PS15.9x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$242.25 | 3.2% | 51.9% | US$5.1b | US$360.57 | PS359.3x | E68.1% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$22.00 | 0% | n/a | HK$68.7b | HK$30.39 | PS8.4x | E59.4% | n/a | Pharmaceuticals & Biotech | ||
BPMU.F | CHF 51.26 | 0% | n/a | CHF 537.6m | CHF 83.64 | PS3.6x | E36.4% | 0% | Pharmaceuticals & Biotech | ||
URGN | US$13.85 | 6.1% | -12.3% | US$551.7m | US$43.10 | PS6.9x | E55.1% | n/a | Pharmaceuticals & Biotech | ||
SWTX | US$35.35 | -1.8% | 46.4% | US$2.6b | US$68.13 | PS30.4x | E75.6% | n/a | Pharmaceuticals & Biotech | ||
TSVT | US$4.87 | 6.1% | 55.1% | US$243.1m | US$10.75 | PS5.7x | E79.6% | n/a | Pharmaceuticals & Biotech |